Slider Bild 3Slider Bild 8Slider Bild 6Slider Bild 13Slider Bild 5Slider Bild 2Slider Bild 7Slider Bild 10Slider Bild 9Slider Bild 4Slider Bild 12Slider Bild 15Slider Bild 14Slider Bild 1Slider Bild 11

18th ISAD

International Symposium on Albumin Dialysis

Hypoperfusion induced shock liver – effect of albumin dialysis

Hypoxic hepatitis (HH), also known as shock liver, is a life-threatening complication accompanying states of oxygen depletion in critically ill patients at the intensive care unit (ICU). Incidence rates of approximately 10% have been reported in critically ill patients at the medical ICU, and mortality rate in these patients was more than 50%. Several risk factors for mortality in HH patients have been identified and include presence of septic shock, sequential organ failure assessment (SOFA) score>10, international normalized ratio (INR) >2, jaundice and necessity of vasopressor therapy. 

Organ failure as acute kidney injury (AKI) is a frequent complication in this population. As a consequence of various definitions being used over the last decades, incidence rates of acute kidney injury is reported to be above 80 percent in this population.

Extracorporeal therapies are a therapeutic cornerstone in patients with HH. However, little is known about its impact on improvement of organ function, reversibility of organ failure and outcome. Therefore, this presentation will summarize the current data on extracorporeal therapies with special focus on therapeutic options of albumin in patients with HH.

Go back